Yulei Du

460 total citations
16 papers, 396 citations indexed

About

Yulei Du is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Yulei Du has authored 16 papers receiving a total of 396 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 7 papers in Cancer Research and 5 papers in Oncology. Recurrent topics in Yulei Du's work include Cancer, Hypoxia, and Metabolism (4 papers), Microtubule and mitosis dynamics (3 papers) and Cancer Mechanisms and Therapy (2 papers). Yulei Du is often cited by papers focused on Cancer, Hypoxia, and Metabolism (4 papers), Microtubule and mitosis dynamics (3 papers) and Cancer Mechanisms and Therapy (2 papers). Yulei Du collaborates with scholars based in China and United States. Yulei Du's co-authors include Daiming Fan, Liu Hong, Huahong Xie, Daiming Fan, Jiugang Song, Fang Yin, Jun Wang, Kaichun Wu, Jie Liu and Taidong Qiao and has published in prestigious journals such as Biochemical and Biophysical Research Communications, Life Sciences and Cancer Letters.

In The Last Decade

Yulei Du

16 papers receiving 392 citations

Peers

Yulei Du

ONCOL

SURGE

Deborah Pajalunga Italy

Jiugang Song China

Iris Kufferath Austria

Conan G. Kinsey United States

Kristen S. Hill United States

Chuanjun Wen China

Ludmila Jirmanova United States

Meta W. Djojosubroto Germany

Zhang Lian-feng China

Kim Moran‐Jones Australia

Deborah Pajalunga Italy

Yulei Du

435 ×1.6

169 ×1.5

ONCOL

60 ×0.6

87 ×1.6

31 ×0.9

SURGE

Citations per year, relative to Yulei Du Yulei Du (= 1×) peers Deborah Pajalunga

Countries citing papers authored by Yulei Du

Since Specialization

Citations

This map shows the geographic impact of Yulei Du's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yulei Du with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yulei Du more than expected).

Fields of papers citing papers by Yulei Du

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yulei Du. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yulei Du. The network helps show where Yulei Du may publish in the future.

Co-authorship network of co-authors of Yulei Du

This figure shows the co-authorship network connecting the top 25 collaborators of Yulei Du. A scholar is included among the top collaborators of Yulei Du based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yulei Du. Yulei Du is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Guo, Cuicui, Hongyu Sun, Yulei Du, et al.. (2025). Specifically blocking αvβ8-mediated TGF-β signaling to reverse immunosuppression by modulating macrophage polarization. Journal of Experimental & Clinical Cancer Research. 44(1). 1–1. 4 indexed citations

Guo, Cuicui, et al.. (2024). Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs. Cancer Immunology Immunotherapy. 73(10). 210–210. 8 indexed citations

Wang, Li, Fang Yin, Yulei Du, et al.. (2010). Depression of MAD2 inhibits apoptosis and increases proliferation and multidrug resistance in gastric cancer cells by regulating the activation of phosphorylated survivin. Tumor Biology. 31(3). 225–232. 17 indexed citations

Du, Yulei, et al.. (2010). [Effects of the spider venom on proliferation of human lung adenocarcinoma cell A549].. PubMed. 13(10). 933–6. 1 indexed citations

Wang, Li, Fang Yin, Yulei Du, et al.. (2009). MAD2 as a Key Component of Mitotic Checkpoint. American Journal of Clinical Pathology. 131(6). 793–801. 25 indexed citations

Xie, Huahong, Jiugang Song, Kaige Liu, et al.. (2008). The Expression of Hypoxia-Inducible Factor-1α in Hepatitis B Virus-Related Hepatocellular Carcinoma: Correlation with Patients’ Prognosis and Hepatitis B Virus X Protein. Digestive Diseases and Sciences. 53(12). 3225–3233. 43 indexed citations

Gao, Juan, Caiping Chen, Liu Hong, et al.. (2007). Expression of Jagged1 and its association with hepatitis B virus X protein in hepatocellular carcinoma. Biochemical and Biophysical Research Communications. 356(2). 341–347. 46 indexed citations

Jin, Haifeng, Yanglin Pan, Lina Zhao, et al.. (2007). p75 Neurotrophin Receptor Suppresses the Proliferation of Human Gastric Cancer Cells. Neoplasia. 9(6). 471–478. 57 indexed citations

Song, Jiugang, Huahong Xie, Zhaorui Lian, et al.. (2006). Enhanced Cell Survival of Gastric Cancer Cells By a Novel Gene URG4. Neoplasia. 8(12). 995–1002. 43 indexed citations

10.

Hu, Shengjuan, Huahong Xie, Yulei Du, et al.. (2006). Phage display selection of peptides that inhibit metastasis ability of gastric cancer cells with high liver-metastatic potential. Biochemical and Biophysical Research Communications. 341(4). 964–972. 28 indexed citations

11.

Du, Yulei, Fang Yin, Changjiang Liu, et al.. (2006). Depression of MAD2 inhibits apoptosis of gastric cancer cells by upregulating Bcl-2 and interfering mitochondrion pathway. Biochemical and Biophysical Research Communications. 345(3). 1092–1098. 28 indexed citations

12.

Yin, Fang, Yulei Du, Wenhua Hu, et al.. (2005). Mad2β, an alternative variant of Mad2 reducing mitotic arrest and apoptosis induced by adriamycin in gastric cancer cells. Life Sciences. 78(12). 1277–1286. 16 indexed citations

13.

Wang, Jun, Kaichun Wu, Feihu Bai, et al.. (2005). Celecoxib could reverse the hypoxia-induced Angiopoietin-2 upregulation in gastric cancer. Cancer Letters. 242(1). 20–27. 16 indexed citations

14.

Qiao, Taidong, et al.. (2005). [A study on the regulatory mechanisms of mitogen-activated protein kinase phosphatase-1 in hypoxia inducible factor-1 trans-activation].. PubMed. 85(8). 555–9. 1 indexed citations

15.

Liu, Changjiang, Yongquan Shi, Yulei Du, et al.. (2005). [Inhibition of the in vitro interaction between hypoxia inducible factor 1alpha and p300 by mitogen-activated protein kinase phosphatase 1].. PubMed. 85(33). 2344–8. 1 indexed citations

16.

Hong, Liu, Ying Piao, Yu Han, et al.. (2005). Zinc ribbon domain-containing 1 (ZNRD1) mediates multidrug resistance of leukemia cells through regulation of P-glycoprotein and Bcl-2. Molecular Cancer Therapeutics. 4(12). 1936–1942. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact